Recommended

Teva close to API business sale
Streamlined rAAV purification enables efficient upstream analytics – access now
First new IPF treatment in US for a decade
Webinar: Radiopharmaceuticals’ time-to-result challenge
AstraZeneca/Daiichi cancer drug boost
Takeda to move away from cell therapy
GSK appoints new CEO
news

NICE recommends Novartis precision brain cancer treatment

1
SHARES

An “innovative, life-extending treatment” for BRAF V600E mutation-positive glioma has been recommended for certain young people on the NHS.

glioma NICE

in clinical trials [the combination treatment was shown] to halt tumour growth for low-grade gliomas for an average of more than two years”

The National Institute for Health and Care Excellence (NICE) has recommended a new targeted drug combination treatment for young people with BRAF V600E mutation-positive glioma.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

Dabrafenib (Finlee) in combination with trametinib (Spexotras) is indicated for patients aged one and over, based on the agency’s proposal in its final draft guidance.  

The combination of medicines, both made by Novartis, have demonstrated in clinical trials an ability to halt tumour growth for low-grade gliomas for an average of more than two years. This is three times longer than current drugs. The combination of Finlee (Dabrafenib) and Spexotras (trametinib) target the proteins affected by the BRAF gene, NICE noted.

According to NICE, gliomas are the most common type of brain cancer in children and young people. Individuals with this aggressive brain cancer have limited treatment options, which include surgery, radiotherapy, chemotherapy, and best supportive care. 

“This recommendation from NICE means eligible children will now be able to access an innovative, life-extending treatment,” stated UK Health Minister, Andrew Stephenson.  

Impact of NICE’s recommendation

Recommendation to make the new precision glioma therapy available on the NHS “is a significant step forward in treatment that has been shown to be easier to take than chemotherapy and very effective in blocking the growth of the disease,” Professor Peter Johnson, NHS National Clinical Director for Cancer commented.

Dabrafenib is administered orally twice per day as tablets. Trametinib is a once-per-day oral solution, NICE added.  

“I am pleased we can recommend this new combination therapy that can give children longer without their tumour growing… This recommendation follows the licensing of both treatments for this type of cancer within the last three months,” Helen Knight, Director of medicines evaluation at NICE explained.  

Further to NICE’s present recommendation, last week, Novartis released promising new data for Fabhalta® (iptacopan) as a treatment for the kidney disease IgA nephropathy (IgAN).

Share via
Share via